Valuation: Keros Therapeutics, Inc.

Market Cap 22Cr 19Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 209.52Cr 82Cr 1.05TCr 83Cr 81Cr 3.49TCr P/E 2026 *
-2.06x
P/E 2027 * -1.83x
Enterprise Value 22Cr 19Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 209.52Cr 82Cr 1.05TCr 83Cr 81Cr 3.49TCr EV / Sales 2026 *
15.1x
EV / Sales 2027 * 17.5x
Free-Float
46.62%
Yield 2026 *
-
Yield 2027 * -
1 day+4.69%
1 week+10.72%
Current month+10.72%
1 month-7.32%
3 months-7.62%
6 months-36.39%
Current year-45.24%
1 week 9.69
Extreme 9.69
11.26
1 month 9.69
Extreme 9.69
11.78
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 01/12/2015
Director of Finance/CFO 55 03/08/2026
Chief Tech/Sci/R&D Officer 53 01/06/2019
Director TitleAgeSince
Chairman 70 01/07/2024
Director/Board Member 63 01/04/2016
Director/Board Member 50 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Buy

Chairman

1,000 0.0051%
01/07/26 Free

Director

28,656 0.1448%
15/06/26 Buy

Chairman

1,000 0.0051%
Change 5-day change 1-year change 3-year change Capi.($)
+4.69%+10.72%-18.79%-69.33% 22Cr
+8.49%+20.55%+70.77%+103.07% 6.81TCr
-1.36%+4.24%+36.08%+64.73% 5.52TCr
-1.09%+32.96%+19.67%+509.20% 2.86TCr
+0.57%+18.87%+55.18%+5.18% 2.4TCr
+2.72%+3.41%-16.11%-12.04% 2.35TCr
-2.00%+6.26%+44.49%-23.80% 1.84TCr
-2.04%+10.84%+31.01%+628.97% 1.64TCr
-3.88%+16.98%+199.30%+350.94% 1.58TCr
+3.58%+1.96%+43.35%+162.22% 1.34TCr
Average +0.97%+11.59%+46.50%+171.91% 2.64TCr
Weighted average by Cap. +1.77%+13.09%+50.73%+161.59%

Financials

2026 *2027 *
Net sales 1.47Cr 1.27Cr 1.19Cr 1.09Cr 2.05Cr 139.75Cr 2.08Cr 14Cr 5.46Cr 70Cr 5.51Cr 5.39Cr 231.56Cr 1.26Cr 1.09Cr 1.02Cr 93.63L 1.76Cr 120.25Cr 1.79Cr 12Cr 4.7Cr 60Cr 4.74Cr 4.64Cr 199.26Cr
Net income -11Cr -9.34Cr -8.72Cr -8Cr -15Cr -1.03TCr -15Cr -102.31Cr -40Cr -514.96Cr -41Cr -40Cr -1.7TCr -14Cr -13Cr -12Cr -11Cr -20Cr -1.38TCr -21Cr -137.35Cr -54Cr -691.35Cr -54Cr -53Cr -2.29TCr
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
07/26/07 $11.15 +4.69% 3,19,629
06/26/06 $10.65 +6.55% 3,86,631
05/26/05 $9.995 -2.49% 3,35,157
04/26/04 $10.25 +1.38% 2,76,934
03/26/03 $10.11 +0.40% 1,54,110
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
11.15USD
Average target price
20.33USD
Spread / Average Target
+82.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock